Form 4: Teva Pharmaceutical Industries Executive Receives Restricted Share Units

Eric A. Hughes, Executive Vice President at Teva Pharmaceutical Industries, was granted 78,616 restricted share units on March 5, 2025, according to a Form 4 filing.

Summary

• Eric A. Hughes, an Executive Vice President at Teva Pharmaceutical Industries, received 78,616 restricted share units on March 5, 2025.
• These restricted share units vest in four equal installments of 19,654 units on March 5 of 2026, 2027, 2028 and 2029.
• Each restricted share unit represents the right to receive one ordinary share or the cash value of one ordinary share, at the discretion of the Human Resources and Compensation Committee.
• The filing was made pursuant to Section 16(a) of the Securities Exchange Act of 1934.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of restricted share units is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders.

Positives

• The grant of restricted share units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Granting restricted share units is a common practice in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Companies like Pfizer, Novartis, and Johnson & Johnson also use restricted stock units as part of their executive compensation packages.
• The vesting schedule is fairly standard, with annual vesting over a period of several years.

Stakeholder Impact

• Shareholders may view the grant as a positive sign of aligning executive interests with long-term company performance.
• Employees may see this as a positive sign of investment in leadership.

Key Dates